RWJBarnabas Health and Rutgers Cancer Institute of New Jersey break ground on Jack & Sheryl Morris Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, in partnership with the New Brunswick Development Corporation, broke ground on the state’s first freestanding cancer hospital. 

At the ceremony, it was also announced that the 510,000-square-foot structure will be named the Jack and Sheryl Morris Cancer Center in recognition of the philanthropic leadership of Jack Morris, who has been a longtime supporter and pillar in New Brunswick development, and his wife, Sheryl.

The 12-story facility, to be located on Somerset Street, will house inpatient, outpatient and ancillary services, as well as state-of-the-art laboratories where research faculty can provide hands-on educational opportunities for students, and enable physician-scientists to translate scientific findings directly to patients. 

The Jack and Sheryl Morris Cancer Center will enable ease of access for imaging and other diagnostic tests, treatment and follow-up exams all in one space. It will also have the capacity to offer wellness and education resources including offerings catered specifically to the needs of cancer survivors. The estimated project cost is $750 million.

The facility, which will be positioned adjacent to the existing Rutgers Cancer Institute building and Robert Wood Johnson University Hospital, also will house state-of-the-art research laboratories. 

The project is expected to be completed in 2024.

Table of Contents

YOU MAY BE INTERESTED IN

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
When it comes to fighting cancer today, collaboration is key. At a time when funding is uncertain, yet innovative breakthroughs are accelerating every day, it’s more important than ever for oncologists, scientists, academic researchers, and community physicians, to come together to share knowledge and gain insights about the forefront of cancer research.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login